Efrat Harel1, Jun Shoji2, Vivek Abraham3, Loan Miller3, Zoltan Laszik4, Tine Thurison5, Andrew King3, Adam Olshen6,7, Joey Leung2, Gyula Szabo4, Byron Hann6, Gunilla Høyer-Hansen4, Charles S Craik1, Flavio Vincenti2. 1. Department of Pharmaceutical Chemistry, University of California, San Francisco, California. 2. Kidney Transplant Service, University of California, San Francisco, California. 3. AbbVie, Renal Discovery, Chicago, Illinois. 4. Department of Pathology, University of California, San Francisco, California. 5. The Finsen Laboratory, Copenhagen University Hospital/Biotech Research & Innovation Centre, Copenhagen, Denmark. 6. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California. 7. Department of Epidemiology and Biostatistics, University of California, San Francisco, California.
Abstract
BACKGROUND: We investigated circulating levels of individual soluble urokinase plasminogen activation receptor (suPAR) forms to determine if specific circulating fragments of suPAR (II-III) and (I) can better serve as clinical biomarkers for focal segmental glomerulosclerosis (FSGS) and the risk of recurrence after transplantation. MATERIALS AND METHODS: Serum levels of intact suPAR and its cleaved forms were measured with two assays, ELISA and TR-FIA. RESULTS: suPAR levels in healthy controls were significantly lower than those who had glomerular diseases but were not significantly different between FSGS patients and glomerular controls. Intact suPAR (I-II-III) levels were noted to be elevated in glomerular diseases including FSGS. uPAR fragment (I) levels measured with the TR-FIA 4 assay were significantly higher in FSGS (695.4 + 91.29 pMol/L) than glomerular controls (239.1 + 40.45 pMol/L, P = 0.001). However, suPAR(I) levels were not significantly different between recurrent FSGS and nonrecurrent FSGS patients. CONCLUSION: Our analysis of suPAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR-FIA assay results suggest that uPAR(I) is a potential biomarker for FSGS but not of its recurrence.
BACKGROUND: We investigated circulating levels of individual soluble urokinase plasminogen activation receptor (suPAR) forms to determine if specific circulating fragments of suPAR (II-III) and (I) can better serve as clinical biomarkers for focal segmental glomerulosclerosis (FSGS) and the risk of recurrence after transplantation. MATERIALS AND METHODS: Serum levels of intact suPAR and its cleaved forms were measured with two assays, ELISA and TR-FIA. RESULTS:suPAR levels in healthy controls were significantly lower than those who had glomerular diseases but were not significantly different between FSGS patients and glomerular controls. Intact suPAR (I-II-III) levels were noted to be elevated in glomerular diseases including FSGS. uPAR fragment (I) levels measured with the TR-FIA 4 assay were significantly higher in FSGS (695.4 + 91.29 pMol/L) than glomerular controls (239.1 + 40.45 pMol/L, P = 0.001). However, suPAR(I) levels were not significantly different between recurrent FSGS and nonrecurrent FSGS patients. CONCLUSION: Our analysis of suPAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR-FIA assay results suggest that uPAR(I) is a potential biomarker for FSGS but not of its recurrence.
Authors: Aleksandra Musiała; Piotr Donizy; Hanna Augustyniak-Bartosik; Katarzyna Jakuszko; Mirosław Banasik; Katarzyna Kościelska-Kasprzak; Magdalena Krajewska; Dorota Kamińska Journal: J Clin Med Date: 2022-06-08 Impact factor: 4.964
Authors: Efrat Harel; Jun Shoji; Vivek Abraham; Loan Miller; Zoltan G Laszik; Andrew King; Dejan Dobi; Gyula Szabo; Byron Hann; Minnie M Sarwal; Charles S Craik; Flavio Vincenti Journal: Transplantation Date: 2020-01 Impact factor: 5.385